Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Summary
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.
2. drug basic information content
(I) deoxypodophyllotoxin
drug name: deoxypodophyllotoxin
dosage form: non-preparation: bulk drug
packing specification: 2Kg
per bag application item: chemical drug: class 1
Application Stage: Clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University
Application Acceptance Number: CXHL1600201 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
(II) Deoxypodophyllotoxin for Injection
Drug Name: Deoxypodophyllotoxin for Injection
Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection
Specification: 100mg Package Specification: 1 bottle per box
Application Item: Chemical Drug: 1 Class
Application Stage: clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University
Application Acceptance Number: CXHL1600202 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
3. Drug Research and Development and Registration
DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.
DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.
Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of
4. on listed companies and risk tips
DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of
is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 25, 2016
More information
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
The water and soil conservation scheme of Daye Peak Mine passed the review.
The water and soil conservation plan of Jinshan limestone mine and Baiyunsi sand shale mine of Daye Peak Cement Company passed expert review a few days ago. In order to effectively prevent and control soil erosion, protect and rationally utilize water and soil resources, reduce water, drought, wind and sand disasters, and improve the ecological environment, in accordance with the "the People's Republic of China Soil and Water Conservation Law", "Management Measures for Soil and Water Conservation Programs for Development and Construction Projects" and other laws and regulations Relevant technical specifications and the requirements of local management departments, Daye Peak commissioned Daye City Soil and Water Conservation Test Station in May this year to prepare soil and water and soil and soil conservation plans for Jinshan limestone mine. Recently, the water and soil conservation plans of the two mines have been prepared and reviewed by experts. After nearly a day of careful review, the participating experts and leaders gave a high evaluation of the plan, and put forward some suggestions and opinions for improvement. At the same time, they fully affirmed Daye Peak's attitude of attaching great importance to the work of soil and water conservation in the mine, and unanimously agreed that the above two The plan passed the review. The service life of water and soil conservation scheme of Jinshan Limestone Mine and Baiyunsi Sand Shale Mine is 5 years. In the next five years, Daye Peak will entrust water and soil conservation supervision and monitoring, and gradually organize the implementation of prevention and control measures in accordance with the plan. By 2021, Daye Peak will prepare a technical evaluation report based on the implementation of the water and soil conservation plan, check the construction and implementation of responsibilities, evaluate the effect of soil erosion prevention and control, and apply for completion acceptance. (Daye Peak)
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-30
Spike Pharmaceuticals Enters Infant Drug Market
Jindal Baby Drug Co., Ltd. Established Peak Pharmaceuticals to Enter Infant Drug Market Recently, Zhejiang Jindal Baby Drug Co., Ltd., a Sino-German joint venture controlled by Peak Pharmaceuticals, completed registration. Peak Pharmaceuticals will use this as a basis to introduce German technology and products and develop the infant drug market. Zhejiang Jindel Baby Drug Co., Ltd. was jointly funded by Jianfeng Pharmaceutical, Germany Gefu Pharmaceutical Co., Ltd. and Zhuhai Hengqin Deyunjia International Trade Co., Ltd., with a registered capital of 20 million yuan, of which Jianfeng Pharmaceutical contributed 11 million yuan in cash, accounting for 55% of the registered capital. Gefu Pharmaceuticals invested 5 million yuan in the evaluation of two proprietary technologies of "diazepam suppository" and "acetaminophen suppository, 25% of the registered capital; De Yunjia contributed 4 million yuan in cash, accounting for 20% of the registered capital. The company's registered address is in Jinxi Development Zone, Jinhua City. It will rent the existing factory building of Jianfeng Pharmaceutical Jinxi Pharmaceutical Factory for renovation, and strive to absorb their respective expertise and adopt appropriate advanced technology and scientific management methods. A modern pharmaceutical enterprise focusing on the research and development, production and sales of pharmaceutical preparations for infants and children. In this cooperation, the corresponding products of "diazepam suppository" and "acetaminophen suppository", which Ge Fu pharmaceutical has invested in with proprietary technology evaluation, have been listed in Germany, among which diazepam suppository is a therapeutic drug for anti-anxiety, sleep disorder and muscle tension increase; acetaminophen is used for fever caused by cold or cold, and also for relieving mild to moderate pain. After the establishment of the joint venture company, it will be based on these two know-how.
2020
07-31
Jinhua City People's Congress Leaders Peak Survey
On July 26, Cai Jian, deputy director of the Jinhua Municipal People's Congress, Chen Zhishi, secretary general of the Standing Committee of the National People's Congress, and a group of four people visited Jianfeng to conduct research on the introduction of talents and technological innovation, and to communicate with Jiang Xiaomeng, Yu Jianhong, Huang Jinlong, Xiang Chongping, Lan Xiaolong and other group company leaders conducted in-depth exchanges. (this newspaper reporter)
2020
07-31